March To A Million

sit-blog-header_2

Join us in helping our National Team Salesforce.com in their March To A Million this year!

In 2015 Salesforce raised an amazing $563,763 making them the #5 National Light The Night Team overall. Their team goal for 2016 is to raise $1,000,000 and if the team hits their goal, their CEO Marc Benioff, will personally match this amount making their total fundraising efforts 2 MILLION dollars which could potentially make them the #2  National Light The Night Team.

Please watch this amazing video from Salesforce.com – Click Here

The Leukemia & Lymphoma Society’s Light The Night Walk funds  life-saving research and support for people battling cancer.  Friends, families and co-workers form fundraising teams and millions of consumers help by donating at retail outlets.  These efforts culminate in inspirational, memorable evening walks in nearly two hundred communities each fall across North America.

The Leukemia & Lymphoma Society (LLS) funded research aims at helping all blood cancer patients live longer, healthier lives.  We will continue to support research through our  innovative and integrated funding programs, until every patient has a safe and effective  therapy.  Currently LLS:

  • Supports research programs in the U.S., Canada, and seven   other countries.
  • Provides services including family support groups, free seminars, direct patient financial aid and co-pay assistance.
  • Educates through our Information Resource Center.
  • Advocates to policy makers at all levels of government.

Come Join Us at our Light The Night Walks this year!  Register Here

 

Beat AML initiative

banner_leukemia_aml

“(As of today,) our website, lls.org, now features more information about acute myeloid leukemia (AML) and LLS’s priority Beat AML initiative.  LLS is leading the offensive against AML, which has not had a change in the standard of care in 40 years and remains one of the most lethal cancers. But we are making significant progress!  LLS had the vision to make a “down payment” for patients with AML in 2009 by partnering with Celator Pharmaceuticals to advance CPX-351, an innovative formulation of two existing therapies, which recently outperformed standard therapy in a Phase 3 clinical trial. This investment has the potential to pay off significantly as the first new treatment in 40 years for patients diagnosed with AML.

Now, through our Beat AML initiative, LLS has convened an unprecedented collaboration of renowned academic researchers, pharmaceutical companies, genomics experts and government, to bring to bear all of our combined resources to develop more effective, precisely targeted treatments for patients diagnosed with AML.”

  • Per Dr. Lou DeGennaro, PhD

 

Also check out these links below to learn more from The Leukemia & Lymphoma Society’s Beat AML Initiative:
https://www.lls.org/beat-aml
http://www.lls.org/content/what-is-beat-aml

The Inspiration Initiative – Jessica Moran, 2016 Honored Hero

Please meet one of our Honored Heroes of the 2016 Boston Light The Night! This is Jessica Moran. She is a true inspiration. There isn’t much that I could write in this week’s blog about Jessica that she hasn’t already said, photographed and lived. Please go to her blog, Facebook, Twitter, or YouTube and see just how strong, beautiful and amazing Ms. Moran is!

12353892_1711023609184015_986098795_a

Blog: https://inspirationinitiative.com/
Facebook: https://www.facebook.com/inspirationinitiative
Twitter: https://twitter.com/jessy_moran

 

And last but certainly not least…You must click on her YouTube and watch her videos!
This was specifically for an Applebee’s fundraiser…
https://youtu.be/0ttf1bRKgJk

 

Keep on moving forward Jessica and we at the Massachusetts Chapter of the Leukemia & Lymphoma Society cannot wait to see you in Boston!!

Significant Advance for Hodgkin Lymphoma Patients

SIGNIFICANT ADVANCE FOR HODGKIN LYMPHOMA PATIENTS
By Andrea Greif | May, 2016
See original article

The Food & Drug Administration’s accelerated approval of an immunotherapy for patients with Hodgkin lymphoma who have failed other treatments is a positive development for patients who face a very poor prognosis.

While Hodgkin lymphoma is now considered one of the most curable forms of cancer – with a more than 86 percent five-year survival rate overall – those patients who relapse after treatment have a much reduced chance of survival.

FDA’s approval of nivolumab (Opdivo®), marks the first approval of this particular approach to therapy for a blood cancer. Nivolumab has previously been approved, either as a single agent or as a combination therapy, for a number of solid tumor cancers, including several types of metastatic melanoma; metastatic non-small cell lung cancer; and renal cell carcinoma.

Nivolumab is among a class of drugs known as immune checkpoint inhibitors. The drug targets a protein called PD1 that prevents the immune system from doing its job. By inhibiting PD1, the immune system’s “brakes” are released harnessing body’s own ability to fight the cancer.

FDA based its approval on Phase 1 and 2 clinical trials that showed favorable overall response rates for these patients – 65 percent.

LLS has supported researchers whose work has shown that inhibiting these immune checkpoint proteins is an effective approach to therapy, and is currently funding several researchers investigating PD1 and PD-L1 inhibitors for other types of lymphomas, including B-cell follicular lymphoma and diffuse large B-cell lymphoma.

fda_approved_0

The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Happy Oncology Nursing Month!

65164ccd1e21f6d996b84c6525f420ea

Please make sure you give an extra high five, hug and a big THANK YOU to all our Oncology nurses this month. They work so hard to help their patients fight and recover every day.

Life After for the ‘Lost Generation.’

dont-be-ashamed-of-your-story-life-quotes-sayings-pictures

“You learn quickly that cancer is an inhospitable house guest: It shows up when you’re least prepared and leaves your place ransacked with no money for a maid.” – Andrew McMahon stated in his patient-advice column for the US News on October 26, 2015.

While we continue to improve treatments and lifespans of those touched by cancer, there is one “lost generation,” that continues to look for more outlets and more efficient treatment plans and therapies and even facilities to complete their journey after diagnosis. The adolescent and young adults are in quite the in between when it comes to these medical advances. Many times doctors and hospitals either place these patients in facilities with children much younger than themselves, or quite the opposite, in facilities with patients sometimes 20 years their senior. It makes for the process to be just that much more grueling on the young cancer fighter.

Many times people who are not directly affected by cancer(s), don’t see the exhausting journey a cancer patient and/or survivor must go through. The entire process can put a large toll on a person’s emotions, body, finances and even relationships, friends, families and significant others alike. Besides physical setbacks, such as feeling “older,” not having enough energy as you once did or even scars, or weight change, this generation can also be struck with financial burdens due to insufficient insurances/job benefits and even high student loans. Not only are we asking this youth to come out with a successful cancer eliminating procedure, but we are now pushing them into the real world with many other burdens placed on heavy shoulders.

Andrew McMahon, now in his early-thirties is a 10-year leukemia survivor and an influential singer-songwriter. Some would know him from former projects such as Jack’s Mannequin and Something Corporate or his recent solo project, Andrew McMahon in the Wilderness. Through McMahon’s cancer treatment he was placed in a facility with others while beyond his own years. Getting the support and understanding therapy options that were offered around him didn’t connect to his youth and emotions he was feeling. The place in his life that he was currently experiencing was entirely different than the other patients around him. While going through his own treatments he could see how this “lost generation” needed a voice to advocate and show what was needed most, support.

McMahon has since started a  charitable foundation called Dear Jack Foundation (dearjackfoundation.com) that supports and advocates for the adolescents and young adults diagnosed with cancer.

amm_wilderness_bg2Andrew McMahon, photo shoot for his Andrew McMahon in the Wilderness project.

The best way to help is be an advocate for those who don’t have a voice. Be a support system for those who just need some assistant to get their voice heard. And those of us who aren’t completing cancer treatments can just be patient, be understanding, but importantly just be there for our loved ones.

Knowles, Kimarie. “Young Adults: Coping with Life After Cancer.” Smithl. Leukemia & Lymphoma Society, Apr. 2016. Web. 29 Apr. 2016. <http://www.lls.org/blog/young-adults-coping-with-life-after-cancer>.

McMahon, Andrew. “Singer Andrew McMahon on the ‘Lost Generation’ of Young Adult Cancer Patients.” U.S News and World Report. U.S News and World Report, 26 Oct. 2015. Web. 29 Apr. 2016. <http://health.usnews.com/health-news/patient-advice/articles/2015/10/26/singer-andrew-mcmahon-on-the-lost-generation-of-young-adult-cancer-patients>.

When non-profit and health retail put their minds together.

345039

On March 16, 2016 Walgreens Co. and the Leukemia & Lymphoma Society (LLS) announced a major collaboration to expand the availability of help, resources and support for blood cancer patients and their families everywhere.

“We are proud to team up with LLS on this transformational approach to empowering and supporting patients through our expert oncology specialized pharmacies across the country. With our aligned missions and commitment to serving patients and families, LLS and Walgreens will make an even greater impact on the health and care of the nearly 1.2 million people in the U.S. living with or in remission from a blood cancer.”  said Richard Ashworth, president, pharmacy and retail operations for Walgreens.

This special collaboration helps patients manage their treatments through oral medications in the comfort of their own homes. It allows specialized pharmacists to continue to be the best resource right at the counter for patients and caregivers. This project continues to show that LLS can provide high-quality, up-to-date information in the most timely manner to those that need it most.

  1. Providing educational tools and resources for enhanced patient support.
  2. Implementing educational and training programs to pharmacists to be more knowledgeable in cancer care and additional care options.
  3. Community engagement and corporate support for Light the Night walk national fundraising campaign

The programs within this collaboration will continue to help capitalize on the leading retail shops within Walgreens Co. and the continuing advancements LLS funds and shares throughout their trials and research. With more specialized pharmacy care and even more access to LLS’ resource center patients can find home treatments, support and caregiving opportunities that match their every need.

http://www.lls.org/news/walgreens-and-lls-create-new-approach-to-support-cancer-patients-in-their-communities?news=LLS%20News%20Network&newsid=12355